Live Breaking News & Updates on Galapagos Gilead Scrap Development Of Ziritaxestat

BPTH On Steady Path, Cancer Genetics On Watch, GLPG/GILD Scrap IPF Drug, REGN s Libtayo Gets FDA Nod
Read on.
1. Bio-Path On A Steady Path
Bio-Path Holdings Inc. (BPTH) has been granted the third U.S. patent, expanding the protection of its DNAbilize platform technology that helps to deliver DNA therapeutics directly to cancer cells.
In addition, the company is expected to be issued a patent related to its lead product candidate, Prexigebersen, in combination with either a cytidine analogue, such as decitabine, or the Bcr-Abl tyrosine kinase inhibitors dasatinib and nilotinib, on February 23, 2021.
Prexigebersen is in a Phase 2 study for blood cancers and Prexigebersen-A, a drug product modification of Prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. ....

Sanofi Libtayo , Regeneron Libtayo , Zynerba Pharmaceuticals Inc , Regeneron Pharmaceuticals Inc , Galapagos Gilead Scrap Development Of Ziritaxestat , Enlivex Therapeutics Ltd , Data Monitoring Committee , Path Holdings Inc , Cancer Genetics Inc , Panbela Therapeutics Inc , Anchiano Therapeutics Ltd , Daily Dose , Cancer Genetic , Steady Path , Path Holdings , Genetics On Watch , Gilead Scrap Development , Independent Data Monitoring , Expanded Label , Regeneron Pharmaceuticals , Priority Review , தகவல்கள் கண்காணிப்பு குழு , பாதை ஹோல்டிங்ஸ் இன்க் , புற்றுநோய் ஜெநெடிக்ஸ் இன்க் , தினசரி டோஸ் , புற்றுநோய் ஜெநெடிக் ,